HSN-003839, a potent and selective USP21 inhibitor with durable antitumor efficacy in vivo
April 15, 2024
HSN-003839 is a ubiquitin carboxyl-terminal hydrolase 21 (USP21) inhibitor discovered by Beijing Pharscin Innobio Co. Ltd. and being developed as a novel anticancer agent.